Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 3,534 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Saline (Placebo Control) Clear all

Conditions: PTSD, Alcohol Use Disorder
Interventions: 40 IU Intranasal Oxytocin, Placebo, Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure; Drug · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 70 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Non-Small Cell Lung Cancer
Interventions: Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Placebo; Radiation · Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 42
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 39 more

Conditions: Kidney Failure, Acute, Renal Replacement Therapy
Interventions: Sodium bicarbonate, Normal saline, Bicarbonate, Placebo; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Facial Filler Injections, Hyaluronic Acid, Tranexamic Acid
Interventions: Hyaluronic Acid (HA), Tranexamic Acid (TXA), Saline (placebo); Procedure · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Surgical Wound Infections
Interventions: Vancomycin, Placebo (Saline Solution); Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: HIV Infections
Interventions: tocilizumab, Placebo; Drug
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Circulatory Perfusion Disorder, Congenital Heart Disease, Single-ventricle
Interventions: Vasopressin, Arginine, Placebo; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 3 Weeks to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Methamphetamine Use Disorder
Interventions: Tirzepatide, Placebo (saline); Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 4
States / cities: Los Angeles, California • San Francisco, California • Tulsa, Oklahoma + 1 more

Conditions: Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder, EBV-Related Malignant Neoplasm, Post-Transplant Lymphoproliferative Disorder
Interventions: Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine, QS21; Procedure · Drug · Biological
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions: Exenatide, Normal Saline; Drug · Other
Lead sponsor: Carl T. Hayden VA Medical Center; Federal
Eligibility: 35 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Asthma, Acute Asthma, Reactive Airway Exacerbation
Interventions: Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg, Prednisolone, prednisone, or methylprednisolone, Albuterol, ipratropium bromide, Ipratropium bromide; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 18 Years
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Inflammatory Bowel Diseases, Clostridium Difficile Infection
Interventions: Bezlotoxumab, Placebo, Fecal Microbiota Transplantation; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Total Hip Arthroplasty
Interventions: intravenous administration of oxytocin, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Spinal Cord Injuries, Type 2 Diabetes
Interventions: Semaglutide Injectable Product, Placebo; Drug · Other
Lead sponsor: Marzieh Salehi; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Abuse, Drug
Interventions: Remimazolam, Midazolam, Saline; Drug · Other
Lead sponsor: Paion UK Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Vomiting, Nausea, Children, Only
Interventions: Inhaled Isopropyl Alcohol, Oral Ondansetron, Inhaled Placebo; Other · Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 7 Years to 17 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Healthy Adult
Interventions: DTI-117, Placebo; Drug
Lead sponsor: Dignify Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Colorectal Surgery
Interventions: Placebo, Ketamine high-dose, Ketamine low-dose; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: COVID-19
Interventions: BI 767551 intravenous, BI 767551 inhaled, Placebo intravenous, Placebo inhaled; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 4
States / cities: Miami Springs, Florida • Amarillo, Texas • Houston, Texas + 1 more

Conditions: Knee Osteoarthritis, Knee Rheumatism
Interventions: Obturator nerve regional block, Adductor canal regional block, Saline; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Enlarged Pores, Sebum Production
Interventions: NT 201, Placebo; Drug
Lead sponsor: Merz North America, Inc.; Industry
Eligibility: 21 Years to 45 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Los Angeles, California • Coral Gables, Florida • Nashville, Tennessee

Conditions: Pain
Interventions: Lidocaine, Placebo (normal saline); Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Clostridium Difficile
Interventions: SER-109, Placebo; Drug
Lead sponsor: Seres Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 30
States / cities: Oceanside, California • Sacramento, California • Ventura, California + 26 more

Conditions: Shingles, Herpes Zoster
Interventions: Zostavax, HZ/su vaccine, Placebo; Biological
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Oxytocin to Enhance Integrated Treatment for AUD and PTSD

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

Use of Bicarbonate to Reduce the Incidence of Acute Renal Failure After Cardiac Surgery

Effect of TXA on Reducing Bruising After Filler Injection

Prevention of Neurosurgical Wound Infections

AIDS 347: IL-6 Blockade in Treated HIV Infection

Early Use of Vasopressin in Post-Fontan Management

Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

Budesonide Inhalation Suspension for Acute Asthma in Children

ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI

Efficacy of Intravenous Oxytocin to Speed Recovery After THA

Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users

Inhaled Isopropyl Alcohol for Treatment of Nausea

A Single Ascending Dose Study of DTI-117 Given Intramuscularly in Healthy Participants.

Effect of Ketamine on Postoperative Clinical Outcomes

A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

Does Adding an Additional Numbing Medication Injection in the Thigh Help With Pain Control After Knee Replacement Surgery?

A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face

Effect of Perioperative Intravenous Lidocaine on Postoperative Quality of Recovery in Patients Undergoing Spine Surgery

SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)

Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds